

NED



• *True innovation in a listed biotech*

• Established in 2013 and listed in 2018, Exopharm (ASX:EX1) was founded on the conviction that exosomes could supersede stem cells and launch a completely new generation of therapeutic approaches to a broad range of medical conditions.
• The Melbourne company now employs 39 staff and continues to grow.

• The new Director roles coincide with Exopharm's conduct of human clinical trials and its recent success in raising capital.

• Up to two new NEDs are sought. Candidates will possess superior board credentials, experience in emergent technology commercialisation and a mindset suited to an early-stage biotechnology company - augmented by extensive networks, gravitas and emotional intelligence.

• Please view the Position Details on www.brookerconsulting.com.au and send a brief governance CV (Word format, up to 5 pages) to career@brookerconsulting.com.au or ring Jeremy Wurm on 0419 529 525 or Lesley Lightfoot on 0458 543 485, in confidence.



www.brookerconsulting.com.au

7/08/10

Board Director Position Brief

Position Title:	Exopharm Non Executive Director
Reporting Structure:	Chair
Company Base Location:	Melbourne, Australia
Position Purpose:	The Board is responsible for providing strategic input and governance oversight of Exopharm, acting in accordance with the Company's Corporate Code of Conduct and the law, in order to best serve the interests of the Company's shareholders, as well as its employees, customers, suppliers, business associates and the local communities where it operates.

Background:

Exopharm was formed in 2013 and listed on the ASX in 2018 with a 'big idea' – that exosomes (or extracellular vesicles [EVs]) could become a new generation of medicines – relevant to both regenerative medicine and precision medicine.

Exopharm is growing as a global leader in the development and commercialisation of exosome-based medicines – part of an emerging new segment in biopharmaceuticals.

Alongside other EV companies such as EVOX Therapeutics and Codiak Biosciences, Exopharm has proprietary intellectual property (IP) relevant to engineered EV (EEV) products as new precision medicines. Exopharm's proprietary LEAP purification technology solves the manufacturing scale problem acknowledged as a key limitation in the use of naïve EVs (NEVs) from adult stem cells as new regenerative medicines.

The new Director roles coincide with Exopharm's conduct of human clinical trials and its recent success in raising capital.

Key Personal contributions:

- Provide useful insights to the Board and Executives to help guide the Company forward
- An interest in medical science and biotechnology
- Help take the Company to the next level and beyond
- Providing a longer-term perspective to the Board and Executives
- Shaping messaging and communications with key audiences
- Building the profile of the Company internationally
- Making key connections into important networks

Other Board member roles and responsibilities:

- Oversee management's implementation of the Company's strategic objectives and its performance generally;
- Provide non-executive leadership and set the strategic objectives of the Company;
- Set the risk appetite within which the Board expects management to operate;
- Build knowledge of the Company's industry and its partners and competitors
- Attend Scheduled Board meetings (currently eight per year) as required.
- Participate in other meetings of the Company and approvals of announcements etc.;
- Approve operating budgets and major capital expenditure;
- Stay abreast of issues relating to innovation commercialisation in Australia and globally;
- Appoint the chairperson of the Board;
- Ensure that the Company has an appropriate risk management framework in place; and Other statutory and normal Board functions.

Qualifications and Experience

- A background in business and business-building;
- Experience in taking emergent technology through early-stage development and commercialisation;
- Academic qualifications to degree or higher, ideally some post graduate study;
- International perspective and experience;
- Demonstrated Board and governance experience;
- Experience in a listed Company environment would be ideal; and
- Strong networks